Fig. 7

Inhibition of NFκB signaling counteracts cisplatin insensitivity in KIAA1522 hyperactivated cells. a Inhibitory effect of QNZ on NFκB signaling in KIAA1522-overexpressed A549 cells was tested by immunoblotting assay. b The control and KIAA1522-overexpressed A549 cells were treated by indicated concentration of cisplatin with or without QNZ (500 nM). Cell viability were analyzed by CCK8 assays. c Clonal formation assays measuring the effect of QNZ on cisplatin-induced growth inhibition in the control and KIAA1522-overexpressed A549 and H1299 cells. The cells were treated with 500 nM QNZ and the indicated concentration of cisplatin for 48 h before crystal violet staining. d The control and KIAA1522 depleted 889 cells were treated by different concentrations of cisplatin with or without QNZ, then analyzed by CCK8 assays to determine cell viability. e Clonal formation assays of the control-sgRNA/Cas9 and kiaa1522-sgRNA/Cas9 expressing 889 cells treated by QNZ and cisplatin for 48 h. f the control and KIAA1522-overexpressed A549 cells were subcutaneously injected into nude mice. From 14 days after cell injection to the 50th day, the mice were treated by cisplatin (7 mg/kg B.W.) once a week and QNZ (1 mg/kg B.W.) twice a week via intraperitoneal injection. Tumor volumes in the last day were compared using t-test, **P < 0.01, ****P < 0.0001